Zonisamide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zonisamide" in English language version.

Last modified: 18:58:51, 6 August 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

3122nih.gov

5^th place

2819web.archive.org

1^st place

2016doi.org

2^nd place

82tga.gov.au

4,353^rd place

2,806^th place

77semanticscholar.org

15^th place

8^th place

43medicines.org.uk

4,892^nd place

3,451^st place

33ds-pharma.co.jp

low place

33clinicaltrials.gov

4,259^th place

3,081^st place

22clincalc.com

5,833^rd place

4,432^nd place

21medicinescomplete.com

low place

11europa.eu

62^nd place

100^th place

11fda.gov

470^th place

329^th place

11medscape.com

1,078^th place

916^th place

11adsabs.harvard.edu

14^th place

9^th place

11drugbank.ca

5,595^th place

low place

11books.google.com

3^rd place

11eisai.co.jp

low place

11springer.com

182^nd place

172^nd place

11bellaireneurology.com

low place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Karaduman AB, Kilic V, Atli-Eklioglu O, Baysal M, Aydogan-Kılıc G, Ucarcan S, et al. (December 2019). "Reproductive toxic effects and possible mechanisms of zonisamide in male rats". Human & Experimental Toxicology. 38 (12): 1384–1396. Bibcode:2019HETox..38.1384K. doi:10.1177/0960327119871094. PMID 31476894. S2CID 201804214.

bellaireneurology.com (Global: low place; English: low place)

Loftus BD (2004). "Zonegran". Archived from the original on 2008-10-23. Retrieved 2006-11-29.

books.google.com (Global: 3^rd place; English: 3^rd place)

Shah J, Kent S, Daniel MC (2002-06-15) [1972]. "Zonisamide". In René H, Levy RH, Brian SM, Perrucca E (eds.). Antiepileptic Drugs (Fifth ed.). Philadelphia: Lippincott Williams & Wilkins. p. 873. ISBN 0-7817-2321-3. Archived from the original on 2021-08-27. Retrieved 2007-11-07.

clincalc.com (Global: 5,833^rd place; English: 4,432^nd place)

Kane SP. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
Kane SP. "Zonisamide - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

clinicaltrials.gov (Global: 4,259^th place; English: 3,081^st place)

University of Cincinnati (2005). "Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity". ClinicalTrials.gov. Archived from the original on 2006-10-13. Retrieved 2006-05-04.
Tuscaloosa Research, Education Advancement Corporation (2005). "Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial". ClinicalTrials.gov. Archived from the original on 2007-05-04. Retrieved 2006-05-04.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2006). "Zonisamide for Weight Reduction in Obese Adults". ClinicalTrials.gov. Archived from the original on 2006-10-11. Retrieved 2006-05-04.

doi.org (Global: 2^nd place; English: 2^nd place)

Grover ND, Limaye RP, Gokhale DV, Patil TR (November–December 2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology. 45 (6): 547–555. doi:10.4103/0253-7613.121266. PMC 3847242. PMID 24347760.
Gidal BE, Resnick T, Smith MC, Wheless JW (February 2024). "Zonisamide: A Comprehensive, Updated Review for the Clinician". Neurology. Clinical Practice. 14 (1) e200210. doi:10.1212/CPJ.0000000000200210. PMC 10759004. PMID 38170117.
Murata M, Hasegawa K, Kanazawa I (January 2007). "Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study". Neurology. 68 (1): 45–50. doi:10.1212/01.wnl.0000250236.75053.16. PMID 17200492. S2CID 894677.
Matsunaga S, Kishi T, Iwata N (2017). "Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis". Journal of Alzheimer's Disease. 56 (4): 1229–1239. doi:10.3233/JAD-161068. PMID 28157097.
Parikh SK, Silberstein SD (March 2019). "Current Status of Antiepileptic Drugs as Preventive Migraine Therapy". Current Treatment Options in Neurology. 21 (4) 16. doi:10.1007/s11940-019-0558-1. PMID 30880369.
Karaduman AB, Kilic V, Atli-Eklioglu O, Baysal M, Aydogan-Kılıc G, Ucarcan S, et al. (December 2019). "Reproductive toxic effects and possible mechanisms of zonisamide in male rats". Human & Experimental Toxicology. 38 (12): 1384–1396. Bibcode:2019HETox..38.1384K. doi:10.1177/0960327119871094. PMID 31476894. S2CID 201804214.
Bookheimer S, Schrader LM, Rausch R, Sankar R, Engel J (February 2005). "Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications". Epilepsia. 46 (2): 236–243. doi:10.1111/j.0013-9580.2005.23904.x. PMID 15679504. S2CID 20730895.
Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, et al. (April 1998). "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data". European Journal of Clinical Pharmacology. 54 (2): 177–183. doi:10.1007/s002280050442. PMID 9626925. S2CID 6508614.
Leppik IE (December 2004). "Zonisamide: chemistry, mechanism of action, and pharmacokinetics". Seizure. 13 (Suppl 1): S5–9, discussion S10. doi:10.1016/j.seizure.2004.04.016. PMID 15511691. S2CID 13458791.
Ueda Y, Doi T, Tokumaru J, Willmore LJ (August 2003). "Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures". Brain Research. Molecular Brain Research. 116 (1–2): 1–6. doi:10.1016/S0169-328X(03)00183-9. PMID 12941455.
Devenish SO, Winters BL, Anderson LL, Arnold JC, McGregor IS, Vaughan CW, et al. (January 2021). "The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations". Neuropharmacology. 182 108371. doi:10.1016/j.neuropharm.2020.108371. PMID 33122032.
Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M, et al. (May 1998). "Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells". Biochimica et Biophysica Acta (BBA) - General Subjects. 1380 (3): 297–304. doi:10.1016/s0304-4165(97)00156-6. PMID 9555064.
Stiff DD, Robicheau JT, Zemaitis MA (January 1992). "Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative". Xenobiotica; The Fate of Foreign Compounds in Biological Systems. 22 (1): 1–11. doi:10.3109/00498259209053097. PMID 1615700.
Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, et al. (April 2012). "Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial". Journal of the Neurological Sciences. 315 (1–2): 137–140. doi:10.1016/j.jns.2011.12.010. PMID 22285275. S2CID 460261.
Gadde KM, Franciscy DM, Wagner HR, Krishnan KR (April 2003). "Zonisamide for weight loss in obese adults: a randomized controlled trial". JAMA. 289 (14): 1820–1825. doi:10.1001/jama.289.14.1820. PMID 12684361.
Hasegawa H (May 2004). "Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital". Current Medical Research and Opinion. 20 (5): 577–580. doi:10.1185/030079904125003313. PMID 15140322. S2CID 43580909.

drugbank.ca (Global: 5,595^th place; English: low place)

"Zonisamide". www.drugbank.ca. Archived from the original on 2019-01-31. Retrieved 2019-01-31.

ds-pharma.co.jp (Global: low place; English: low place)

Dainippon Sumitomo Pharma Co. Ltd. (2005). "Company History". Company Information. Dainippon Sumitomo Co., Ltd. Archived from the original on 13 February 2006. Retrieved 12 November 2005.
Dainippon Pharmaceutical Co. Ltd. (2004). "Transfer of Rights Agreement for North America and Europe Reached on Zonegran". News Releases for Dainippon Pharmaceutical in 2004. Dainippon Sumitomo Pharma Co., Ltd. Archived from the original on 13 February 2006. Retrieved 12 November 2005.
Dainippon Pharmaceutical Co. Ltd. (2005). "Dainippon Pharmaceutical and Eisai Conclude Agreement for the Development, Manufacture and Marketing of the Anti-Epileptic Agent Zonisamide in Asia". Dainippon Pharmaceutical News Releases for 2005. Dainippon Sumitomo Pharma Co., Ltd. Archived from the original on 22 February 2006. Retrieved 12 November 2005.

eisai.co.jp (Global: low place; English: low place)

"Eisai Announces Launch of Zonegran (zonisamide), Treatment For Epilepsy In the UK and Germany". Eisai 2005 News Releases. Eisai Co., Ltd. 2005. Archived from the original on 2005-10-28. Retrieved 12 November 2005.

europa.eu (Global: 62^nd place; English: 100^th place)

ema.europa.eu

"Zonegran EPAR". European Medicines Agency. 10 March 2005. Retrieved 24 May 2024.

fda.gov (Global: 470^th place; English: 329^th place)

accessdata.fda.gov

"Drug Approval Package: Zonegran (Zonisomide) NDA #20-789". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 29 March 2021. Retrieved 20 July 2022.

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

medicines.org.uk

"Zonegran 25, 50, 100 mg Hard Capsules". electronic Medicines Compendium. Eisai Ltd. 8 October 2013. Archived from the original on 12 January 2015. Retrieved 18 November 2013.
"Zonegran 25, 50, 100 mg Hard Capsules". Electronic Medicines Compendium (eMC). Archived from the original on 14 February 2019. Retrieved 12 April 2017.

emc.medicines.org.uk

Eisai Ltd. (2005). "Zonegran Summary of Product Characteristics". electronic Medicines Compendium. Medicines.org.uk. Archived from the original on 8 November 2005. Retrieved 13 November 2005.

medicinescomplete.com (Global: low place; English: low place)

Brayfield A, ed. (8 March 2016). "Zonisamide: Martindale: The Complete Drug Reference". MedicinesComplete. London, UK: Pharmaceutical Press. Archived from the original on 27 August 2021. Retrieved 19 August 2017.

medscape.com (Global: 1,078^th place; English: 916^th place)

reference.medscape.com

"zonisamide (Rx) - Zonegran". Medscape Reference. WebMD. 2024-12-09. Archived from the original on 4 December 2013. Retrieved 18 November 2013.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Grover ND, Limaye RP, Gokhale DV, Patil TR (November–December 2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology. 45 (6): 547–555. doi:10.4103/0253-7613.121266. PMC 3847242. PMID 24347760.
Gidal BE, Resnick T, Smith MC, Wheless JW (February 2024). "Zonisamide: A Comprehensive, Updated Review for the Clinician". Neurology. Clinical Practice. 14 (1) e200210. doi:10.1212/CPJ.0000000000200210. PMC 10759004. PMID 38170117.
Murata M, Hasegawa K, Kanazawa I (January 2007). "Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study". Neurology. 68 (1): 45–50. doi:10.1212/01.wnl.0000250236.75053.16. PMID 17200492. S2CID 894677.
Matsunaga S, Kishi T, Iwata N (2017). "Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis". Journal of Alzheimer's Disease. 56 (4): 1229–1239. doi:10.3233/JAD-161068. PMID 28157097.
Parikh SK, Silberstein SD (March 2019). "Current Status of Antiepileptic Drugs as Preventive Migraine Therapy". Current Treatment Options in Neurology. 21 (4) 16. doi:10.1007/s11940-019-0558-1. PMID 30880369.
Karaduman AB, Kilic V, Atli-Eklioglu O, Baysal M, Aydogan-Kılıc G, Ucarcan S, et al. (December 2019). "Reproductive toxic effects and possible mechanisms of zonisamide in male rats". Human & Experimental Toxicology. 38 (12): 1384–1396. Bibcode:2019HETox..38.1384K. doi:10.1177/0960327119871094. PMID 31476894. S2CID 201804214.
Bookheimer S, Schrader LM, Rausch R, Sankar R, Engel J (February 2005). "Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications". Epilepsia. 46 (2): 236–243. doi:10.1111/j.0013-9580.2005.23904.x. PMID 15679504. S2CID 20730895.
Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, et al. (April 1998). "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data". European Journal of Clinical Pharmacology. 54 (2): 177–183. doi:10.1007/s002280050442. PMID 9626925. S2CID 6508614.
Leppik IE (December 2004). "Zonisamide: chemistry, mechanism of action, and pharmacokinetics". Seizure. 13 (Suppl 1): S5–9, discussion S10. doi:10.1016/j.seizure.2004.04.016. PMID 15511691. S2CID 13458791.
Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (March 1990). "Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain". Medical Journal of Osaka University. 39 (1–4): 13–17. PMID 1369646.
Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H (March 1990). "[3H]zonisamide binding in rat brain". Medical Journal of Osaka University. 39 (1–4): 19–22. PMID 1369647.
Ueda Y, Doi T, Tokumaru J, Willmore LJ (August 2003). "Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures". Brain Research. Molecular Brain Research. 116 (1–2): 1–6. doi:10.1016/S0169-328X(03)00183-9. PMID 12941455.
Devenish SO, Winters BL, Anderson LL, Arnold JC, McGregor IS, Vaughan CW, et al. (January 2021). "The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations". Neuropharmacology. 182 108371. doi:10.1016/j.neuropharm.2020.108371. PMID 33122032.
Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M, et al. (May 1998). "Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells". Biochimica et Biophysica Acta (BBA) - General Subjects. 1380 (3): 297–304. doi:10.1016/s0304-4165(97)00156-6. PMID 9555064.
Stiff DD, Robicheau JT, Zemaitis MA (January 1992). "Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative". Xenobiotica; The Fate of Foreign Compounds in Biological Systems. 22 (1): 1–11. doi:10.3109/00498259209053097. PMID 1615700.
Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, et al. (April 2012). "Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial". Journal of the Neurological Sciences. 315 (1–2): 137–140. doi:10.1016/j.jns.2011.12.010. PMID 22285275. S2CID 460261.
Gadde KM, Franciscy DM, Wagner HR, Krishnan KR (April 2003). "Zonisamide for weight loss in obese adults: a randomized controlled trial". JAMA. 289 (14): 1820–1825. doi:10.1001/jama.289.14.1820. PMID 12684361.
Hasegawa H (May 2004). "Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital". Current Medical Research and Opinion. 20 (5): 577–580. doi:10.1185/030079904125003313. PMID 15140322. S2CID 43580909.

dailymed.nlm.nih.gov

"Zonegran- zonisamide capsule". DailyMed. 20 August 2021. Archived from the original on 27 January 2021. Retrieved 19 July 2022.
"Zonisade- zonisamide suspension". DailyMed. 15 July 2022. Retrieved 21 January 2023.

ncbi.nlm.nih.gov

Grover ND, Limaye RP, Gokhale DV, Patil TR (November–December 2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology. 45 (6): 547–555. doi:10.4103/0253-7613.121266. PMC 3847242. PMID 24347760.
Gidal BE, Resnick T, Smith MC, Wheless JW (February 2024). "Zonisamide: A Comprehensive, Updated Review for the Clinician". Neurology. Clinical Practice. 14 (1) e200210. doi:10.1212/CPJ.0000000000200210. PMC 10759004. PMID 38170117.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Murata M, Hasegawa K, Kanazawa I (January 2007). "Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study". Neurology. 68 (1): 45–50. doi:10.1212/01.wnl.0000250236.75053.16. PMID 17200492. S2CID 894677.
Karaduman AB, Kilic V, Atli-Eklioglu O, Baysal M, Aydogan-Kılıc G, Ucarcan S, et al. (December 2019). "Reproductive toxic effects and possible mechanisms of zonisamide in male rats". Human & Experimental Toxicology. 38 (12): 1384–1396. Bibcode:2019HETox..38.1384K. doi:10.1177/0960327119871094. PMID 31476894. S2CID 201804214.
Bookheimer S, Schrader LM, Rausch R, Sankar R, Engel J (February 2005). "Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications". Epilepsia. 46 (2): 236–243. doi:10.1111/j.0013-9580.2005.23904.x. PMID 15679504. S2CID 20730895.
Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, et al. (April 1998). "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data". European Journal of Clinical Pharmacology. 54 (2): 177–183. doi:10.1007/s002280050442. PMID 9626925. S2CID 6508614.
Leppik IE (December 2004). "Zonisamide: chemistry, mechanism of action, and pharmacokinetics". Seizure. 13 (Suppl 1): S5–9, discussion S10. doi:10.1016/j.seizure.2004.04.016. PMID 15511691. S2CID 13458791.
Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, et al. (April 2012). "Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial". Journal of the Neurological Sciences. 315 (1–2): 137–140. doi:10.1016/j.jns.2011.12.010. PMID 22285275. S2CID 460261.
Hasegawa H (May 2004). "Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital". Current Medical Research and Opinion. 20 (5): 577–580. doi:10.1185/030079904125003313. PMID 15140322. S2CID 43580909.

springer.com (Global: 182^nd place; English: 172^nd place)

adisinsight.springer.com

"Bupropion/zonisamide". AdisInsight. Springer. 20 May 2017. Archived from the original on 19 August 2017. Retrieved 19 August 2017.

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

tga.gov.au

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

ebs.tga.gov.au

"Zonegran Product Information" (PDF). TGA eBusiness Services. SciGen (Australia) Pty Ltd. 4 April 2013. Archived from the original on 15 October 2018. Retrieved 18 November 2013.

web.archive.org (Global: 1^st place; English: 1^st place)

"Zonegran- zonisamide capsule". DailyMed. 20 August 2021. Archived from the original on 27 January 2021. Retrieved 19 July 2022.
"Zonegran Product Information" (PDF). TGA eBusiness Services. SciGen (Australia) Pty Ltd. 4 April 2013. Archived from the original on 15 October 2018. Retrieved 18 November 2013.
Brayfield A, ed. (8 March 2016). "Zonisamide: Martindale: The Complete Drug Reference". MedicinesComplete. London, UK: Pharmaceutical Press. Archived from the original on 27 August 2021. Retrieved 19 August 2017.
"Drug Approval Package: Zonegran (Zonisomide) NDA #20-789". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 29 March 2021. Retrieved 20 July 2022.
Eisai Ltd. (2005). "Zonegran Summary of Product Characteristics". electronic Medicines Compendium. Medicines.org.uk. Archived from the original on 8 November 2005. Retrieved 13 November 2005.
"Zonegran 25, 50, 100 mg Hard Capsules". electronic Medicines Compendium. Eisai Ltd. 8 October 2013. Archived from the original on 12 January 2015. Retrieved 18 November 2013.
"zonisamide (Rx) - Zonegran". Medscape Reference. WebMD. 2024-12-09. Archived from the original on 4 December 2013. Retrieved 18 November 2013.
"Zonegran 25, 50, 100 mg Hard Capsules". Electronic Medicines Compendium (eMC). Archived from the original on 14 February 2019. Retrieved 12 April 2017.
"Zonisamide". www.drugbank.ca. Archived from the original on 2019-01-31. Retrieved 2019-01-31.
Shah J, Kent S, Daniel MC (2002-06-15) [1972]. "Zonisamide". In René H, Levy RH, Brian SM, Perrucca E (eds.). Antiepileptic Drugs (Fifth ed.). Philadelphia: Lippincott Williams & Wilkins. p. 873. ISBN 0-7817-2321-3. Archived from the original on 2021-08-27. Retrieved 2007-11-07.
Dainippon Sumitomo Pharma Co. Ltd. (2005). "Company History". Company Information. Dainippon Sumitomo Co., Ltd. Archived from the original on 13 February 2006. Retrieved 12 November 2005.
Dainippon Pharmaceutical Co. Ltd. (2004). "Transfer of Rights Agreement for North America and Europe Reached on Zonegran". News Releases for Dainippon Pharmaceutical in 2004. Dainippon Sumitomo Pharma Co., Ltd. Archived from the original on 13 February 2006. Retrieved 12 November 2005.
Dainippon Pharmaceutical Co. Ltd. (2005). "Dainippon Pharmaceutical and Eisai Conclude Agreement for the Development, Manufacture and Marketing of the Anti-Epileptic Agent Zonisamide in Asia". Dainippon Pharmaceutical News Releases for 2005. Dainippon Sumitomo Pharma Co., Ltd. Archived from the original on 22 February 2006. Retrieved 12 November 2005.
"Eisai Announces Launch of Zonegran (zonisamide), Treatment For Epilepsy In the UK and Germany". Eisai 2005 News Releases. Eisai Co., Ltd. 2005. Archived from the original on 2005-10-28. Retrieved 12 November 2005.
University of Cincinnati (2005). "Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity". ClinicalTrials.gov. Archived from the original on 2006-10-13. Retrieved 2006-05-04.
Tuscaloosa Research, Education Advancement Corporation (2005). "Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial". ClinicalTrials.gov. Archived from the original on 2007-05-04. Retrieved 2006-05-04.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2006). "Zonisamide for Weight Reduction in Obese Adults". ClinicalTrials.gov. Archived from the original on 2006-10-11. Retrieved 2006-05-04.
"Bupropion/zonisamide". AdisInsight. Springer. 20 May 2017. Archived from the original on 19 August 2017. Retrieved 19 August 2017.
Loftus BD (2004). "Zonegran". Archived from the original on 2008-10-23. Retrieved 2006-11-29.

Zonisamide (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

bellaireneurology.com (Global: low place; English: low place)

books.google.com (Global: 3rd place; English: 3rd place)

clincalc.com (Global: 5,833rd place; English: 4,432nd place)

clinicaltrials.gov (Global: 4,259th place; English: 3,081st place)

doi.org (Global: 2nd place; English: 2nd place)

drugbank.ca (Global: 5,595th place; English: low place)

ds-pharma.co.jp (Global: low place; English: low place)

eisai.co.jp (Global: low place; English: low place)

europa.eu (Global: 62nd place; English: 100th place)

ema.europa.eu

fda.gov (Global: 470th place; English: 329th place)

accessdata.fda.gov

medicines.org.uk (Global: 4,892nd place; English: 3,451st place)

medicines.org.uk

emc.medicines.org.uk

medicinescomplete.com (Global: low place; English: low place)

medscape.com (Global: 1,078th place; English: 916th place)

reference.medscape.com

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

ncbi.nlm.nih.gov

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

springer.com (Global: 182nd place; English: 172nd place)

adisinsight.springer.com

tga.gov.au (Global: 4,353rd place; English: 2,806th place)

tga.gov.au

ebs.tga.gov.au

web.archive.org (Global: 1st place; English: 1st place)

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

clincalc.com (Global: 5,833^rd place; English: 4,432^nd place)

clinicaltrials.gov (Global: 4,259^th place; English: 3,081^st place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugbank.ca (Global: 5,595^th place; English: low place)

europa.eu (Global: 62^nd place; English: 100^th place)

fda.gov (Global: 470^th place; English: 329^th place)

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

medscape.com (Global: 1,078^th place; English: 916^th place)

nih.gov (Global: 5^th place; English: 5^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

springer.com (Global: 182^nd place; English: 172^nd place)

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

web.archive.org (Global: 1^st place; English: 1^st place)